Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients

References

• BernardiMPNganSYMichaelMMolecular biology of anal squamous cell carcinoma: implications for future research and clinical interventionLancet Oncol20151616e611e62126678214
   PubMed Web of Science ®Google Scholar
• JamesRDGlynne-JonesRMeadowsHMMitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trialLancet Oncol201314651652423578724
   PubMed Web of Science ®Google Scholar
• RenehanAGSaundersMPSchofieldPFO’DwyerSTPatterns of local disease failure and outcome after salvage surgery in patients with anal cancerBr J Surg200592560561415739215
   PubMed Web of Science ®Google Scholar
• Glynne-JonesRKadalayilLMeadowsHMACT II Study GroupTumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trialAnn Oncol20142581616162224827136
   PubMed Web of Science ®Google Scholar
• Glynne-JonesRRenehanACurrent treatment of anal squamous cell carcinomaHematol Oncol Clin North Am20122661315135023116582
   PubMed Web of Science ®Google Scholar
• GilbertDCGlynne-JonesRIntensity-modulated radiotherapy in anal cancer: where do we go from here?Clin Oncol (R Coll Radiol)201325315315422921809
   PubMed Web of Science ®Google Scholar
• SchillerDECummingsBJRaiSOutcomes of salvage surgery for squamous cell carcinoma of the anal canalAnn Surg Oncol200714102780278917638059
   PubMed Web of Science ®Google Scholar
• GilbertDCWilliamsAAllanKp16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapyRadiother Oncol2013109114615124021343
   PubMed Web of Science ®Google Scholar
• BordonYImmunotherapy: checkpoint parleyNat Rev Cancer2015151325503072
   PubMed Web of Science ®Google Scholar
• KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol20082667770418173375
   PubMed Web of Science ®Google Scholar
• ChangCHQiuJO’SullivanDMetabolic competition in the tumor microenvironment is a driver of cancer progressionCell201516261229124126321679
   PubMed Web of Science ®Google Scholar
• BaptistaMZSarianLODerchainSFPintoGAVassalloJPrognostic significance of PD-L1 and PD-L2 in breast cancerHum Pathol2016471788426541326
   PubMed Web of Science ®Google Scholar
• YokoyamaSMiyoshiHNakashimaKPrognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinomaClin Cancer Res201622184727473427166394
   PubMed Web of Science ®Google Scholar
• ThompsonEDZahurakMMurphyAPatterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stromaGut201766579480126801886
   PubMed Web of Science ®Google Scholar
• UdagerAMLiuTYSkalaSLFrequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approachesAnn Oncol20162791706171227217541
   PubMed Web of Science ®Google Scholar
• ChoueiriTKFayAPGrayKPPD-L1 expression in nonclear-cell renal cell carcinomaAnn Oncol201425112178218425193987
   PubMed Web of Science ®Google Scholar
• HuWHMiyaiKCajas-MonsonLCLuoLLiuLRamamoorthySLTumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinomaJ Surg Oncol2015112442142626287957
   PubMed Web of Science ®Google Scholar
• NghiemPTBhatiaSLipsonEJPD-1 blockade with pembrolizumab in advanced Merkel-cell carcinomaN Engl J Med2016374262542255227093365
   PubMed Web of Science ®Google Scholar
• KudoMImmune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trialsOncology201792Suppl 1506228147363
   PubMedGoogle Scholar
• Serup-HansenELinnemannDSkovrider-RuminskiWHøgdallEGeertsenPFHavsteenHHuman papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canalJ Clin Oncol201432171812181724821878
   PubMed Web of Science ®Google Scholar
• SchlechtNFBrandwein-GenslerMNuovoGJA comparison of clinically utilized human papillomavirus detection methods in head and neck cancerMod Pathol201124101295130521572401
   PubMed Web of Science ®Google Scholar
• XieQKZhaoYJPanTProgrammed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinomaOncoimmunology201657e118125227622038
   PubMed Web of Science ®Google Scholar
• ZouMXPengABLvGHExpression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosisAm J Transl Res2016873274328727508049
   PubMed Web of Science ®Google Scholar
• TsutsumiSSaekiHNakashimaYProgrammed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinomaCancer Sci201710861119112728294486
   PubMed Web of Science ®Google Scholar
• SaigusaSToiyamaYTanakaKImplication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapyInt J Clin Oncol201621594695226919982
   PubMed Web of Science ®Google Scholar
• WuCZhuYJiangJZhaoJZhangXGXuNImmunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significanceActa Histochem20061081192416530813
   PubMed Web of Science ®Google Scholar
• NomiTShoMAkahoriTClinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancerClin Cancer Res20071372151215717404099
   PubMed Web of Science ®Google Scholar
• DroeserRAHirtCViehlCTClinical impact of programmed cell death ligand 1 expression in colorectal cancerEur J Cancer20134992233224223478000
   PubMed Web of Science ®Google Scholar
• OhigashiYShoMYamadaYClinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancerClin Cancer Res20051182947295315837746
   PubMed Web of Science ®Google Scholar
• MuenstSSoysalSDGaoFObermannECOertliDGillandersWEThe presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancerBreast Cancer Res Treat2013139366767623756627
   PubMed Web of Science ®Google Scholar
• ThompsonRHDongHLohseCMPD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinomaClin Cancer Res20071361757176117363529
   PubMed Web of Science ®Google Scholar
• GevenslebenHDietrichDGolletzCThe immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancerClin Cancer Res20162281969197726573597
   PubMed Web of Science ®Google Scholar
• TaubeJMAndersRAYoungGDColocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapeSci Transl Med20124127127ra37
   PubMed Web of Science ®Google Scholar
• SchmidtLHKümmelAGörlichDPD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroupsPLoS One2015108e013602326313362
   PubMed Web of Science ®Google Scholar
• BalermpasPMartinDWielandUHuman papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: rationale for immunotherapyOncoimmunology201763e128833128405521
   PubMed Web of Science ®Google Scholar
• GovindarajanRGujjaSSiegelERProgrammed cell death-ligand 1 (PD-L1) expression in anal cancerAm J Clin Oncol Epub20161115
   Web of Science ®Google Scholar
• ZhangYHuangSGongDQinYShenQProgrammed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancerCell Mol Immunol20107538939520514052
   PubMed Web of Science ®Google Scholar
• HinoRKabashimaKKatoYTumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanomaCancer201011671757176620143437
   PubMed Web of Science ®Google Scholar
• SchalperKAVelchetiVCarvajalDIn situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomasClin Cancer Res201420102773278224647569
   PubMed Web of Science ®Google Scholar
• Twyman-Saint VictorCRechAJMaityARadiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerNature2015520754737337725754329
   PubMed Web of Science ®Google Scholar
• SchultheisAMScheelAHOzretićLPD-L1 expression in small cell neuroendocrine carcinomasEur J Cancer201551342142625582496
   PubMed Web of Science ®Google Scholar
• GrulichAEvan LeeuwenMTFalsterMOVajdicCMIncidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysisLancet20073709581596717617273
   PubMed Web of Science ®Google Scholar
• MorrisVKSalemMENimeiriHNivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 studyLancet Oncol201718444645328223062
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• PowlesTEderJPFineGDMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature2014515752855856225428503
   PubMed Web of Science ®Google Scholar
• TengMWNgiowSFRibasASmythMJClassifying cancers based on T-cell infiltration and PD-L1Cancer Res201575112139214525977340
   PubMed Web of Science ®Google Scholar
• BadoualCHansSMerillonNPD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancerCancer Res201373112813823135914
   PubMed Web of Science ®Google Scholar
• Lyford-PikeSPengSYoungGDEvidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinomaCancer Res20137361733174123288508
   PubMed Web of Science ®Google Scholar
• OttenhofSRDjajadiningratRSde JongJThygesenHHHorenblasSJordanovaESExpression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV statusJ Urol20171973 Pt 169069727697578
   PubMed Web of Science ®Google Scholar
• KimHSLeeJYLimSHAssociation between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinomaCancer Res Treat201648252753626511814
   PubMed Web of Science ®Google Scholar
• SharonEStreicherHGoncalvesPChenHXImmune checkpoint inhibitors in clinical trialsChin J Cancer201433943444425189716
   PubMedGoogle Scholar